Approved in late 2016, Spinraza (nusinersen) remains the only drug cleared to treat spinal muscular atrophy (SMA), but multiple companies are looking to grab a share of the blockbuster market established by Cambridge, Mass.-based Biogen Inc. and its development partner, Ionis Pharmaceuticals Inc., of Carlsbad, Calif. Read More
